Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055810 | 0.84 | SLC6A3 (0.40) | SMN1; SMN2HPGDALDH1A1L3MBTL1GAA | |
| SCHEMBL27875923 | 0.79 | — | — | |
| SCHEMBL28631331 | 0.79 | — | — | |
| SCHEMBL19987653 | 0.78 | L3MBTL1 (0.36) | SMN1; SMN2HPGDALDH1A1L3MBTL1GAA | |
| SCHEMBL16553217 | 0.76 | L3MBTL1 (0.35) | SMN1; SMN2HPGDALDH1A1L3MBTL1GAA | |
| SCHEMBL24006379 | 0.75 | — | — | |
| Ammonia Solution, Strong SCHEMBL7016380 | 0.74 | HCAR2 (0.46) | SMN1; SMN2HPGDALDH1A1L3MBTL1GAA | |
| SCHEMBL270189 | 0.74 | L3MBTL1 (0.35) | SMN1; SMN2HPGDALDH1A1L3MBTL1GAA | |
| Vinyl Ether SCHEMBL28222295 | 0.73 | L3MBTL1 (0.33) | SMN1; SMN2HPGDALDH1A1L3MBTL1GAA | |
| SCHEMBL5475612 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2491785-A1 | Method and compositions for treating HIV infections | Purdue Research Foundation (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
| EP-2120562-A2 | METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS | Purdue Research Foundation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008133734-A2 | METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS | PURDUE RESEARCH FOUNDATION (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SERPINB1, HPN, PRSS1 | SMN1; SMN2 3881/4885HPGD 895/4885ALDH1A1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.